1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Merck of Germany's Hunt For MS BTKi Partner Boosted By Evobrutinib Data

 
• By Sten Stovall

German Merck tells Scrip its quest to find a partner for its Bruton’s tyrosine kinase inhibitor evobrutinib should be helped by positive 24-week Phase IIb data in relapsing multiple sclerosis.

nerve cells, concept for neurodegenerative and neurological disease
Merck KGaA Says Latest Strong Evobrutinib MS Data Will Help With Partnering Its BTKi • Source: Shutterstock

Merck KGAA's investigational Bruton's tyrosine kinase (BTK) inhibitor has generated fresh positive safety and efficacy data from a Phase IIb proof-of-concept study in multiple sclerosis which the family-owned company hopes will further help to lure a potential partner to advance the asset in MS as well as lupus and rheumatoid arthritis, executives of the German pharma company told Scrip.

They were speaking in Berlin where Merck presented positive Phase IIb data on its BTK inhibitor evobrutinib. It is the first study to show proof of concept for a BTK inhibitor in MS

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

More from R&D